About the Company
since its founding in 2004, vaxart has pursued a vision of advancing vaccines—to make them as tablets rather than injections. the company’s proprietary oral vaccine delivery platform is suitable to deliver any recombinant vaccine, positioning vaxart to introduce oral forms of multiple vaccines in the rapidly growing global vaccines market.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $VXRT News
Vaxart, Inc. (NASDAQ:VXRT) Q4 2023 Earnings Call Transcript
Q4 2023 Earnings Call March 14, 2024 Vaxart, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the ...
Estimating The Intrinsic Value Of Vaxart, Inc. (NASDAQ:VXRT)
Using the 2 Stage Free Cash Flow to Equity, Vaxart fair value estimate is US$0.90 With US$1.08 share price, Vaxart appears to be trading close to its estimated fair value The US$5.00 analyst price ...
Vaxart Inc (VXRT) Reports Full Year 2023 Financial Results
Revenue: Reported annual revenue of $7.379 million for 2023. Net Loss: Net loss widened to $82.465 million, or $0.57 per ...
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
Revenue for the full year 2023 was $7.4 million, compared to $0.1 million for 2022. Revenue in 2023 was primarily from revenue recognized for work performed under Vaxart’s grant from the Bill & ...
Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director
Michael J. Finney, Ph.D. to Continue as Chairman of the Board of DirectorsSOUTH SAN FRANCISCO, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- ...
Vaxart Inc VXRT
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Vaxart (VXRT) Price Target Increased by 5.26% to 5.10
The average one-year price target for Vaxart (NasdaqCM:VXRT) has been revised to 5.10 / share.This is an increase of 5.26% from the prior estimate of 4.84 dated January 16, 2024. The price target ...
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
March 14, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced its business update and financial results for the full year 2023. “We are excited to welcome Steve Lo as Vaxart’s ...
Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director
SOUTH SAN FRANCISCO, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that it has ...
Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director
March 06, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that it has appointed Steven Lo as President and Chief Executive Officer and a ...
Loading the latest forecasts...